Lynparza (olaparib) — Medica
Ovarian, fallopian tube, or primary peritoneal cancer – maintenance, combination therapy
Initial criteria
- age ≥ 18 years
- used in combination with bevacizumab
- homologous recombination deficiency (HRD)-positive disease confirmed by an approved test (HRD-positive includes BRCA mutation-positive disease)
- complete or partial response to first-line platinum-based chemotherapy regimen
Approval duration
1 year